{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T10:55:29Z","timestamp":1763549729760,"version":"3.45.0"},"reference-count":163,"publisher":"Elsevier","isbn-type":[{"type":"print","value":"9780443344817"}],"license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025]]},"DOI":"10.1016\/bs.acr.2025.06.005","type":"book-chapter","created":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T08:30:58Z","timestamp":1753259458000},"page":"159-194","source":"Crossref","is-referenced-by-count":0,"title":["In search of a targetable immune profile for acute myeloid leukemia"],"prefix":"10.1016","member":"78","reference":[{"issue":"9","key":"10.1016\/bs.acr.2025.06.005_bib1","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1016\/j.ajpath.2020.05.007","article-title":"The surprising story of IL-2: From experimental models to clinical application","volume":"190","author":"Abbas","year":"2020","journal-title":"The American Journal of Pathology"},{"issue":"10","key":"10.1016\/bs.acr.2025.06.005_bib2","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1038\/s41589-023-01316-3","article-title":"MHC-II dynamics are maintained in HLA-DR allotypes to ensure catalyzed peptide exchange","volume":"19","author":"Abualrous","year":"2023","journal-title":"Nature Chemical Biology"},{"issue":"Suppl 1","key":"10.1016\/bs.acr.2025.06.005_bib3","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1182\/blood-2024-211343","article-title":"A Phase I study of nivolumab in combination with ipilimumab for the treatment of patients with high risk or refractory\/relapsed acute myeloid leukemia following allogeneic stem cell transplantation","volume":"144","author":"Alatrash","year":"2024","journal-title":"Blood"},{"issue":"3","key":"10.1016\/bs.acr.2025.06.005_bib4","doi-asserted-by":"crossref","first-page":"202","DOI":"10.5581\/1516-8484.20110054","article-title":"The expression of CD56 antigen is associated with poor prognosis in patients with acute myeloid leukemia","volume":"33","author":"Alegretti","year":"2011","journal-title":"Revista brasileira de hematologia e hemoterapia"},{"issue":"6","key":"10.1016\/bs.acr.2025.06.005_bib5","article-title":"BiTEs, DARTS, BiKEs and TriKEs-are antibody based therapies changing the future treatment of AML?","volume":"11","author":"Allen","year":"2021","journal-title":"Life (Basel)"},{"issue":"22","key":"10.1016\/bs.acr.2025.06.005_bib6","doi-asserted-by":"crossref","first-page":"3855","DOI":"10.3390\/cancers16223855","article-title":"Acute myeloid leukemia: Diagnosis and evaluation by flow cytometry","volume":"16","author":"Ally","year":"2024","journal-title":"Cancers"},{"issue":"10","key":"10.1016\/bs.acr.2025.06.005_bib7","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1038\/s43018-023-00634-8","article-title":"Immunotargeting of a recurrent AML-specific neoantigen","volume":"4","author":"Apavaloaei","year":"2023","journal-title":"Nature Cancer"},{"issue":"22","key":"10.1016\/bs.acr.2025.06.005_bib8","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1182\/blood-2017-09-797712","article-title":"Gemtuzumab ozogamicin for acute myeloid leukemia","volume":"130","author":"Appelbaum","year":"2017","journal-title":"Blood"},{"issue":"8","key":"10.1016\/bs.acr.2025.06.005_bib9","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.3324\/haematol.2021.279486","article-title":"A novel CD34-specific T-cell engager efficiently depletes acute myeloid leukemia and leukemic stem cells in vitro and in vivo<\/i&gt","volume":"107","author":"Arruda","year":"2022","journal-title":"Haematologica"},{"issue":"5","key":"10.1016\/bs.acr.2025.06.005_bib10","doi-asserted-by":"crossref","DOI":"10.1002\/cbic.202200510","article-title":"Applications of terminal deoxynucleotidyl transferase enzyme in biotechnology","volume":"24","author":"Ashley","year":"2023","journal-title":"Chembiochem: a European Journal of Chemical Biology"},{"issue":"10","key":"10.1016\/bs.acr.2025.06.005_bib11","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1038\/s41375-024-02351-2","article-title":"Rational combinatorial targeting by adapter CAR-T-cells (AdCAR-T) prevents antigen escape in acute myeloid leukemia","volume":"38","author":"Atar","year":"2024","journal-title":"Leukemia: Official Journal of the Leukemia Society of America, Leukemia Research Fund, U. K"},{"issue":"7","key":"10.1016\/bs.acr.2025.06.005_bib12","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1182\/blood-2008-07-168468","article-title":"CTLA4 blockade with ipilimumab to treat relapse of malignancy after allogeneic hematopoietic cell transplantation","volume":"113","author":"Bashey","year":"2009","journal-title":"Blood"},{"issue":"1","key":"10.1016\/bs.acr.2025.06.005_bib13","doi-asserted-by":"crossref","first-page":"42","DOI":"10.5414\/NP300698","article-title":"PD1 (CD279) and PD-L1 (CD274, B7H1) expression in primary central nervous system lymphomas (PCNSL)","volume":"33","author":"Berghoff","year":"2014","journal-title":"Clinical Neuropathology"},{"issue":"7198","key":"10.1016\/bs.acr.2025.06.005_bib14","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1038\/nature07036","article-title":"Induction and effector functions of TH17 cells","volume":"453","author":"Bettelli","year":"2008","journal-title":"Nature"},{"issue":"8","key":"10.1016\/bs.acr.2025.06.005_bib15","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1016\/S0021-9258(18)64634-4","article-title":"Calf thymus polymerase","volume":"235","author":"Bollum","year":"1960","journal-title":"Journal of Biological Chemistry"},{"issue":"4","key":"10.1016\/bs.acr.2025.06.005_bib16","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1309\/PLN1NA4QB2PC1CMQ","article-title":"The expression of myeloid antigens CD13 and\/or CD33 is a marker of ALK+ anaplastic large cell lymphomas","volume":"130","author":"Bovio","year":"2008","journal-title":"American Journal of Clinical Pathology"},{"issue":"3","key":"10.1016\/bs.acr.2025.06.005_bib17","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1111\/cts.13467","article-title":"First-in-human study of JNJ-63709178, a CD123\/CD3 targeting antibody, in relapsed\/refractory acute myeloid leukemia","volume":"16","author":"Boyiadzis","year":"2023","journal-title":"Clinical and Translational Science"},{"issue":"3","key":"10.1016\/bs.acr.2025.06.005_bib18","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1093\/ajcp\/107.3.283","article-title":"Aberrant expression of CD19 as a marker of monocytic lineage in acute myelogenous leukemia","volume":"107","author":"Brandt","year":"1997","journal-title":"American Journal of Clinical Pathology"},{"issue":"7","key":"10.1016\/bs.acr.2025.06.005_bib19","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1111\/trf.15397","article-title":"The effects of monoclonal anti\u2010CD47 on RBCs, compatibility testing, and transfusion requirements in refractory acute myeloid leukemia","volume":"59","author":"Brierley","year":"2019","journal-title":"Transfusion"},{"issue":"23","key":"10.1016\/bs.acr.2025.06.005_bib20","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1182\/blood.V126.23.560.560","article-title":"A recurrent immunophenotype at diagnosis independently identifies high risk pediatric AML: A report from the children's oncology group trial AAML0531","volume":"126","author":"Brodersen","year":"2015","journal-title":"Blood"},{"issue":"1","key":"10.1016\/bs.acr.2025.06.005_bib21","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1111\/j.1365-2141.1992.tb06401.x","article-title":"The role of an anti-myeloperoxidase antibody in the diagnosis and classification of acute leukaemia: A comparison with light and electron microscopy cytochemistry","volume":"80","author":"Buccheri","year":"1992","journal-title":"British Journal of Haematology"},{"issue":"11","key":"10.1016\/bs.acr.2025.06.005_bib22","doi-asserted-by":"crossref","first-page":"5421","DOI":"10.4049\/jimmunol.170.11.5421","article-title":"A role for the B7-1\/B7-2:CD28\/CTLA-4 pathway during negative selection","volume":"170","author":"Buhlmann","year":"2003","journal-title":"Journal of Immunology"},{"issue":"2","key":"10.1016\/bs.acr.2025.06.005_bib23","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.immuni.2024.01.013","article-title":"The B7: CD28 family and friends: Unraveling coinhibitory interactions","volume":"57","author":"Burke","year":"2024","journal-title":"Immunity"},{"issue":"21","key":"10.1016\/bs.acr.2025.06.005_bib24","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1182\/blood.V118.21.582.582","article-title":"The addition of Gemtuzumab ozogamicin to intensive chemotherapy in older patients with AML produces a significant improvement in overall survival: results of the UK NCRI AML16 randomized trial","volume":"118","author":"Burnett","year":"2011","journal-title":"Blood"},{"issue":"5","key":"10.1016\/bs.acr.2025.06.005_bib25","first-page":"392","article-title":"CD117 (c-kit) is a restricted antigen of acute myeloid leukemia and characterizes early differentiative levels of M5 FAB subtype","volume":"83","author":"Cascavilla","year":"1998","journal-title":"Haematologica"},{"issue":"24","key":"10.1016\/bs.acr.2025.06.005_bib26","doi-asserted-by":"crossref","first-page":"2330","DOI":"10.1056\/NEJMoa1808777","article-title":"Immune escape of relapsed AML cells after allogeneic transplantation","volume":"379","author":"Christopher","year":"2018","journal-title":"The New England Journal of Medicine"},{"issue":"2","key":"10.1016\/bs.acr.2025.06.005_bib27","doi-asserted-by":"crossref","first-page":"7057","DOI":"10.4081\/hr.2017.7057","article-title":"Acute myeloid leukemia with RAM immunophenotype: A pediatric case with unusual morphologic features","volume":"9","author":"Conces","year":"2017","journal-title":"Hematology Reports"},{"issue":"7","key":"10.1016\/bs.acr.2025.06.005_bib28","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/S1470-2045(19)30150-0","article-title":"Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): A multicentre, randomised, controlled, open-label, phase 3 trial","volume":"20","author":"Cortes","year":"2019","journal-title":"The Lancet Oncology"},{"issue":"7","key":"10.1016\/bs.acr.2025.06.005_bib29","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/S1470-2045(18)30240-7","article-title":"Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: An open-label, multicentre, single-arm, phase 2 trial","volume":"19","author":"Cortes","year":"2018","journal-title":"The Lancet Oncology"},{"issue":"1","key":"10.1016\/bs.acr.2025.06.005_bib30","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1038\/s41467-018-08201-x","article-title":"Selective hematopoietic stem cell ablation using CD117-antibody-drug-conjugates enables safe and effective transplantation with immunity preservation","volume":"10","author":"Czechowicz","year":"2019","journal-title":"Nature Communications"},{"issue":"13","key":"10.1016\/bs.acr.2025.06.005_bib31","doi-asserted-by":"crossref","first-page":"4351","DOI":"10.1182\/blood-2007-01-070284","article-title":"Impaired responsiveness to T-cell receptor stimulation and defective negative selection of thymocytes in CCR7-deficient mice","volume":"110","author":"Davalos-Misslitz","year":"2007","journal-title":"Blood"},{"issue":"2","key":"10.1016\/bs.acr.2025.06.005_bib32","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/s41375-018-0357-9","article-title":"Targeting FLT3 mutations in AML: Review of current knowledge and evidence","volume":"33","author":"Daver","year":"2019","journal-title":"Leukemia: Official Journal of the Leukemia Society of America, Leukemia Research Fund, U. K"},{"issue":"24","key":"10.1016\/bs.acr.2025.06.005_bib33","doi-asserted-by":"crossref","first-page":"2182","DOI":"10.1182\/blood.2019004710","article-title":"A multicenter phase 1 study of nivolumab for relapsed hematologic malignancies after allogeneic transplantation","volume":"135","author":"Davids","year":"2020","journal-title":"Blood"},{"issue":"7","key":"10.1016\/bs.acr.2025.06.005_bib34","first-page":"723","article-title":"Receptor protein-tyrosine phosphatase signalling in development","volume":"43","author":"den Hertog","year":"1999","journal-title":"The International Journal of Developmental Biology"},{"issue":"17","key":"10.1016\/bs.acr.2025.06.005_bib35","doi-asserted-by":"crossref","first-page":"4002","DOI":"10.1002\/j.1460-2075.1994.tb06716.x","article-title":"The catalytic activity of the CD45 membrane-proximal phosphatase domain is required for TCR signaling and regulation","volume":"13","author":"Desai","year":"1994","journal-title":"The EMBO Journal"},{"issue":"4","key":"10.1016\/bs.acr.2025.06.005_bib36","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1007\/s40272-024-00634-w","article-title":"Inotuzumab ozogamicin: First pediatric approval","volume":"26","author":"Dhillon","year":"2024","journal-title":"Paediatric Drugs"},{"key":"10.1016\/bs.acr.2025.06.005_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2024.107437","article-title":"Artificial intelligence-based prediction models for acute myeloid leukemia using real-life data: A DATAML registry study","volume":"136","author":"Didi","year":"2024","journal-title":"Leukemia Research"},{"issue":"6407","key":"10.1016\/bs.acr.2025.06.005_bib38","doi-asserted-by":"crossref","DOI":"10.1126\/science.aao2933","article-title":"Differential IL-2 expression defines developmental fates of follicular versus nonfollicular helper T cells","volume":"361","author":"DiToro","year":"2018","journal-title":"Science (New York, N. Y.)"},{"issue":"4","key":"10.1016\/bs.acr.2025.06.005_bib39","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","article-title":"Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel","volume":"129","author":"D\u00f6hner","year":"2017","journal-title":"Blood"},{"issue":"12","key":"10.1016\/bs.acr.2025.06.005_bib40","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"D\u00f6hner","year":"2022","journal-title":"Blood"},{"key":"10.1016\/bs.acr.2025.06.005_bib41","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.3389\/fimmu.2020.01710","article-title":"PD-L1 is expressed and promotes the expansion of regulatory T cells in acute myeloid leukemia","volume":"11","author":"Dong","year":"2020","journal-title":"Frontiers in Immunology"},{"issue":"2","key":"10.1016\/bs.acr.2025.06.005_bib42","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1007\/s10620-019-05787-0","article-title":"Expression of programmed death ligand 1 is associated with the prognosis of intrahepatic cholangiocarcinoma","volume":"65","author":"Dong","year":"2020","journal-title":"Digestive Diseases and Sciences"},{"issue":"6","key":"10.1016\/bs.acr.2025.06.005_bib43","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0145-2126(00)00021-7","article-title":"Identification of acute myeloid leukemia patients with diminished expression of CD13 myeloid transcripts by competitive reverse transcription polymerase chain reaction (RT-PCR)","volume":"24","author":"Dybkaer","year":"2000","journal-title":"Leukemia Research"},{"issue":"5","key":"10.1016\/bs.acr.2025.06.005_bib44","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/j.ccell.2024.04.008","article-title":"Comprehensive peripheral blood immunoprofiling reveals five immunotypes with immunotherapy response characteristics in patients with cancer","volume":"42","author":"Dyikanov","year":"2024","journal-title":"Cancer Cell"},{"issue":"6","key":"10.1016\/bs.acr.2025.06.005_bib45","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2014.39","article-title":"Distribution and levels of cell surface expression of CD33 and CD123 in acute myeloid leukemia","volume":"4","author":"Ehninger","year":"2014","journal-title":"Blood Cancer Journal"},{"issue":"12","key":"10.1016\/bs.acr.2025.06.005_bib46","doi-asserted-by":"crossref","first-page":"4722","DOI":"10.1182\/blood-2004-09-3796","article-title":"Molecular basis for positive and negative signaling by the natural killer cell receptor 2B4 (CD244)","volume":"105","author":"Eissmann","year":"2005","journal-title":"Blood"},{"issue":"2","key":"10.1016\/bs.acr.2025.06.005_bib47","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.4049\/jimmunol.177.2.1052","article-title":"CTLA-4 overexpression inhibits T cell responses through a CD28-B7-dependent mechanism","volume":"177","author":"Engelhardt","year":"2006","journal-title":"Journal of Immunology"},{"issue":"2","key":"10.1016\/bs.acr.2025.06.005_bib48","doi-asserted-by":"crossref","first-page":"889","DOI":"10.4049\/jimmunol.1303389","article-title":"Investigation of soluble and transmembrane CTLA-4 isoforms in serum and microvesicles","volume":"193","author":"Esposito","year":"2014","journal-title":"Journal of Immunology"},{"issue":"1","key":"10.1016\/bs.acr.2025.06.005_bib49","article-title":"Aberrant expression of T cell activation markers and upregulation of Tregs in bone marrow and peripheral blood in acute myeloid leukemia patients","volume":"28","author":"Fang","year":"2023","journal-title":"Hematology (Amsterdam, Netherlands)"},{"issue":"3","key":"10.1016\/bs.acr.2025.06.005_bib50","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/j.ymthe.2021.11.013","article-title":"Targeting HLA-DR loss in hematologic malignancies with an inhibitory chimeric antigen receptor","volume":"30","author":"Fei","year":"2022","journal-title":"Molecular Therapy"},{"issue":"4","key":"10.1016\/bs.acr.2025.06.005_bib51","doi-asserted-by":"crossref","first-page":"707","DOI":"10.3324\/haematol.2016.151555","article-title":"CD244 maintains the proliferation ability of leukemia initiating cells through SHP-2\/p27kip1 signaling","volume":"102","author":"Feifei","year":"2017","journal-title":"Haematologica"},{"issue":"2","key":"10.1016\/bs.acr.2025.06.005_bib52","first-page":"A473","article-title":"444\u2005GTB-3550 tri-specific killer engager TriKE\u2122 drives NK cells expansion and cytotoxicity in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) patients","volume":"9","author":"Felices","year":"2021","journal-title":"Journal for Immuno Therapy of Cancer"},{"issue":"7","key":"10.1016\/bs.acr.2025.06.005_bib53","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1182\/blood-2008-06-161539","article-title":"CXCR4 expression and biologic activity in acute myeloid leukemia are dependent on oxygen partial pressure","volume":"113","author":"Fiegl","year":"2009","journal-title":"Blood"},{"issue":"5","key":"10.1016\/bs.acr.2025.06.005_bib54","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1038\/nri2297","article-title":"CCR7 and its ligands: balancing immunity and tolerance","volume":"8","author":"F\u00f6rster","year":"2008","journal-title":"Nature Reviews. Immunology"},{"issue":"10","key":"10.1016\/bs.acr.2025.06.005_bib55","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1038\/s43018-023-00642-8","article-title":"A T cell receptor targeting a recurrent driver mutation in FLT3 mediates elimination of primary human acute myeloid leukemia in vivo","volume":"4","author":"Giannakopoulou","year":"2023","journal-title":"Nature Cancer"},{"issue":"19","key":"10.1016\/bs.acr.2025.06.005_bib56","doi-asserted-by":"crossref","first-page":"3016","DOI":"10.1182\/blood-2013-10-533398","article-title":"CD16xCD33 bispecific killer cell engager (BiKE) activates NK cells against primary MDS and MDSC CD33+ targets","volume":"123","author":"Gleason","year":"2014","journal-title":"Blood"},{"issue":"11","key":"10.1016\/bs.acr.2025.06.005_bib57","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1038\/s41587-023-01684-0","article-title":"Single-cell transcriptomic atlas-guided development of CAR-T cells for the treatment of acute myeloid leukemia","volume":"41","author":"Gottschlich","year":"2023","journal-title":"Nature Biotechnology"},{"issue":"650","key":"10.1016\/bs.acr.2025.06.005_bib58","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abn3248","article-title":"CKS1 inhibition depletes leukemic stem cells and protects healthy hematopoietic stem cells in acute myeloid leukemia","volume":"14","author":"Grey","year":"2022","journal-title":"Science Translational Medicine"},{"issue":"8","key":"10.1016\/bs.acr.2025.06.005_bib59","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1111\/cas.12459","article-title":"Th17 cells and interleukin-17 increase with poor prognosis in patients with acute myeloid leukemia","volume":"105","author":"Han","year":"2014","journal-title":"Cancer Science"},{"issue":"22","key":"10.1016\/bs.acr.2025.06.005_bib60","doi-asserted-by":"crossref","first-page":"7061","DOI":"10.1073\/pnas.1415675112","article-title":"Th17 cells give rise to Th1 cells that are required for the pathogenesis of colitis","volume":"112","author":"Harbour","year":"2015","journal-title":"Proceedings of the National Academy of Sciences"},{"issue":"1","key":"10.1016\/bs.acr.2025.06.005_bib61","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1038\/s41375-018-0180-3","article-title":"Coexpression profile of leukemic stem cell markers for combinatorial targeted therapy in AML","volume":"33","author":"Haubner","year":"2019","journal-title":"Leukemia: Official Journal of the Leukemia Society of America, Leukemia Research Fund, U. K"},{"issue":"10","key":"10.1016\/bs.acr.2025.06.005_bib62","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1182\/blood.2019002779","article-title":"Bispecific and split CAR T cells targeting CD13 and TIM3 eradicate acute myeloid leukemia","volume":"135","author":"He","year":"2020","journal-title":"Blood"},{"issue":"3","key":"10.1016\/bs.acr.2025.06.005_bib63","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.immuni.2015.02.010","article-title":"CD5 instructs extrathymic regulatory T cell development in response to self and tolerizing antigens","volume":"42","author":"Henderson","year":"2015","journal-title":"Immunity"},{"issue":"6","key":"10.1016\/bs.acr.2025.06.005_bib64","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.annonc.2020.02.018","article-title":"Acute myeloid leukaemia in adult patients: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"31","author":"Heuser","year":"2020","journal-title":"Annals of Oncology: Official Journal of the European Society for Medical Oncology \/ ESMO"},{"issue":"1","key":"10.1016\/bs.acr.2025.06.005_bib65","article-title":"Tumor-infiltrating CD45RO+ memory T lymphocytes predict favorable clinical outcome in solid tumors","volume":"7","author":"Hu","year":"2017","journal-title":"Scientific Reports"},{"issue":"1","key":"10.1016\/bs.acr.2025.06.005_bib66","doi-asserted-by":"crossref","first-page":"9803","DOI":"10.1038\/s41598-022-13764-3","article-title":"Role of CD47 in tumor immunity: A potential target for combination therapy","volume":"12","author":"Huang","year":"2022","journal-title":"Scientific Reports"},{"key":"10.1016\/bs.acr.2025.06.005_bib67","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.molimm.2021.09.007","article-title":"The glycosylation status of MHC class I molecules impacts their interactions with TAPBPR","volume":"139","author":"Ilca","year":"2021","journal-title":"Molecular Immunology"},{"issue":"2","key":"10.1016\/bs.acr.2025.06.005_bib68","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/ni877","article-title":"CD45 ectodomain controls interaction with GEMs and Lck activity for optimal TCR signaling","volume":"4","author":"Irles","year":"2003","journal-title":"Nature Immunology"},{"issue":"6","key":"10.1016\/bs.acr.2025.06.005_bib69","doi-asserted-by":"crossref","DOI":"10.3390\/cells9061376","article-title":"PD-1: Its discovery, involvement in cancer immunotherapy, and beyond","volume":"9","author":"Ishida","year":"2020","journal-title":"Cells"},{"issue":"44","key":"10.1016\/bs.acr.2025.06.005_bib70","article-title":"A rare case of mixed phenotype acute leukemia: acute myeloid leukemia to early T-cell precursor acute lymphoblastic leukemia transformation","volume":"10","author":"Jasmin","year":"2022","journal-title":"The Southwest Respiratory and Critical Care Chronicles"},{"issue":"3","key":"10.1016\/bs.acr.2025.06.005_bib71","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/s41408-018-0069-4","article-title":"Bone marrow CD8 T cells express high frequency of PD-1 and exhibit reduced anti-leukemia response in newly diagnosed AML patients","volume":"8","author":"Jia","year":"2018","journal-title":"Blood Cancer Journal"},{"issue":"11","key":"10.1016\/bs.acr.2025.06.005_bib72","doi-asserted-by":"crossref","DOI":"10.3390\/ph14111105","article-title":"The potential advantage of targeting both PD-L1\/PD-L2\/PD-1 and IL-10-IL-10R pathways in acute myeloid leukemia","volume":"14","author":"Jimbu","year":"2021","journal-title":"Pharmaceuticals (Basel)"},{"issue":"4","key":"10.1016\/bs.acr.2025.06.005_bib73","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1084\/jem.20160801","article-title":"PD-L1 on tumor cells is sufficient for immune evasion in immunogenic tumors and inhibits CD8 T cell cytotoxicity","volume":"214","author":"Juneja","year":"2017","journal-title":"The Journal of Experimental Medicine"},{"issue":"5","key":"10.1016\/bs.acr.2025.06.005_bib74","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1038\/ncb3158","article-title":"The ITIM-containing receptor LAIR1 is essential for acute myeloid leukaemia development","volume":"17","author":"Kang","year":"2015","journal-title":"Nature Cell Biology"},{"issue":"2","key":"10.1016\/bs.acr.2025.06.005_bib75","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/s41408-021-00425-3","article-title":"Acute myeloid leukemia: Current progress and future directions","volume":"11","author":"Kantarjian","year":"2021","journal-title":"Blood Cancer Journal"},{"issue":"2","key":"10.1016\/bs.acr.2025.06.005_bib76","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.ymthe.2023.11.028","article-title":"Soluble CTLA-4 attenuates T cell activation and modulates anti-tumor immunity","volume":"32","author":"Kennedy","year":"2024","journal-title":"Molecular Therapy"},{"key":"10.1016\/bs.acr.2025.06.005_bib77","doi-asserted-by":"crossref","DOI":"10.1038\/nrdp.2016.10","article-title":"Acute myeloid leukaemia","volume":"2","author":"Khwaja","year":"2016","journal-title":"Nature Reviews. Disease Primers"},{"issue":"9","key":"10.1016\/bs.acr.2025.06.005_bib78","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1182\/blood.V81.9.2399.2399","article-title":"Clinical importance of CD7 expression in acute myelocytic leukemia","volume":"81","author":"Kita","year":"1993","journal-title":"Blood"},{"issue":"11","key":"10.1016\/bs.acr.2025.06.005_bib79","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1038\/s41375-024-02326-3","article-title":"CXCR4 as a therapeutic target in acute myeloid leukemia","volume":"38","author":"Korbecki","year":"2024","journal-title":"Leukemia: Official Journal of the Leukemia Society of America, Leukemia Research Fund, U. K"},{"issue":"8","key":"10.1016\/bs.acr.2025.06.005_bib80","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1182\/bloodadvances.2018017517","article-title":"A CD123-targeting antibody-drug conjugate, IMGN632, designed to eradicate AML while sparing normal bone marrow cells","volume":"2","author":"Kovtun","year":"2018","journal-title":"Blood Advances"},{"issue":"3","key":"10.1016\/bs.acr.2025.06.005_bib81","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1182\/blood-2013-08-523548","article-title":"CD33 target validation and sustained depletion of AML blasts in long-term cultures by the bispecific T-cell-engaging antibody AMG 330","volume":"123","author":"Krupka","year":"2014","journal-title":"Blood"},{"issue":"14","key":"10.1016\/bs.acr.2025.06.005_bib82","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1007\/s40265-017-0802-5","article-title":"Inotuzumab ozogamicin: First global approval","volume":"77","author":"Lamb","year":"2017","journal-title":"Drugs"},{"issue":"1","key":"10.1016\/bs.acr.2025.06.005_bib83","doi-asserted-by":"crossref","first-page":"113","DOI":"10.3324\/haematol.2018.188888","article-title":"Gemtuzumab ozogamicin for de novo acute myeloid leukemia: final efficacy and safety updates from the open-label, phase III ALFA-0701 trial","volume":"104","author":"Lambert","year":"2019","journal-title":"Haematologica"},{"issue":"Suppl 1","key":"10.1016\/bs.acr.2025.06.005_bib84","doi-asserted-by":"crossref","first-page":"6209","DOI":"10.1182\/blood-2022-158029","article-title":"Safety and activity of flotetuzumab in pediatric and young adult patients with relapsed\/refractory acute myeloid leukemia: results from the COG PEPN1812 Phase 1 trial","volume":"140","author":"Lamble","year":"2022","journal-title":"Blood"},{"issue":"8","key":"10.1016\/bs.acr.2025.06.005_bib85","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20231222","article-title":"Five decades of natural killer cell discovery","volume":"221","author":"Lanier","year":"2024","journal-title":"Journal of Experimental Medicine"},{"issue":"2","key":"10.1016\/bs.acr.2025.06.005_bib86","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12020303","article-title":"CD22 expression in B-cell acute lymphoblastic leukemia: Biological significance and implications for inotuzumab therapy in adults","volume":"12","author":"Lanza","year":"2020","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/bs.acr.2025.06.005_bib87","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1084\/jem.184.1.183","article-title":"T cell responses affected by aminopeptidase N (CD13)-mediated trimming of major histocompatibility complex class II-bound peptides","volume":"184","author":"Larsen","year":"1996","journal-title":"The Journal of Experimental Medicine"},{"issue":"4","key":"10.1016\/bs.acr.2025.06.005_bib88","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1111\/j.1365-2141.2006.06472.x","article-title":"CTLA-4 expressed by chemoresistant, as well as untreated, myeloid leukaemia cells can be targeted with ligands to induce apoptosis","volume":"136","author":"Laurent","year":"2007","journal-title":"British Journal of Haematology"},{"issue":"18","key":"10.1016\/bs.acr.2025.06.005_bib89","doi-asserted-by":"crossref","first-page":"3909","DOI":"10.1182\/blood-2009-02-206946","article-title":"Peripheral blood T cells in acute myeloid leukemia (AML) patients at diagnosis have abnormal phenotype and genotype and form defective immune synapses with AML blasts","volume":"114","author":"Le Dieu","year":"2009","journal-title":"Blood"},{"issue":"26","key":"10.1016\/bs.acr.2025.06.005_bib90","doi-asserted-by":"crossref","first-page":"3403","DOI":"10.1182\/blood-2017-05-782292","article-title":"Midostaurin approved for FLT3-mutated AML","volume":"129","author":"Levis","year":"2017","journal-title":"Blood"},{"issue":"3","key":"10.1016\/bs.acr.2025.06.005_bib91","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.yexmp.2007.08.010","article-title":"Aberrant expression of T-cell markers in acute myeloid leukemia","volume":"83","author":"Lewis","year":"2007","journal-title":"Experimental and Molecular Pathology"},{"issue":"21","key":"10.1016\/bs.acr.2025.06.005_bib92","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1182\/blood.V122.21.1359.1359","article-title":"Coinhibitory expression profiling of AML blasts identifies HVEM as prognostic marker in AML","volume":"122","author":"Lichtenegger","year":"2013","journal-title":"Blood"},{"issue":"1","key":"10.1016\/bs.acr.2025.06.005_bib93","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s13045-016-0381-z","article-title":"Is CD47 an innate immune checkpoint for tumor evasion?","volume":"10","author":"Liu","year":"2017","journal-title":"Journal of Hematology & Oncology"},{"issue":"Supplement 1","key":"10.1016\/bs.acr.2025.06.005_bib94","doi-asserted-by":"crossref","first-page":"2846","DOI":"10.1182\/blood-2023-179325","article-title":"1- and 5-Year survival for adults with acute myeloid leukaemia and 30-Day mortality after initial systemic anti-cancer therapy, with an exploration of factors associated with poorer outcomes: Data from a National Registry in England, 2013-2020","volume":"142","author":"Liu","year":"2023","journal-title":"Blood"},{"issue":"5","key":"10.1016\/bs.acr.2025.06.005_bib95","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.immuni.2020.04.011","article-title":"The CD47-SIRP\u03b1 immune checkpoint","volume":"52","author":"Logtenberg","year":"2020","journal-title":"Immunity"},{"issue":"22","key":"10.1016\/bs.acr.2025.06.005_bib96","doi-asserted-by":"crossref","DOI":"10.1172\/JCI169519","article-title":"LAIR-1 agonism as a therapy for acute myeloid leukemia","volume":"133","author":"Lovewell","year":"2023","journal-title":"The Journal of Clinical Investigation"},{"issue":"1","key":"10.1016\/bs.acr.2025.06.005_bib97","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1007\/s00262-024-03847-7","article-title":"Loop33\u2009\u00d7\u2009123 CAR-T targeting CD33 and CD123 against immune escape in acute myeloid leukemia","volume":"74","author":"Ma","year":"2024","journal-title":"Cancer Immunology, Immunotherapy: CII"},{"issue":"Suppl 1","key":"10.1016\/bs.acr.2025.06.005_bib98","doi-asserted-by":"crossref","first-page":"4842","DOI":"10.1182\/blood-2023-189132","article-title":"Phase I study of FT538 + daratumumab for treatment of relapsed\/refractory AML","volume":"142","author":"Maakaron","year":"2023","journal-title":"Blood"},{"issue":"2","key":"10.1016\/bs.acr.2025.06.005_bib99","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.cell.2009.05.045","article-title":"CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells","volume":"138","author":"Majeti","year":"2009","journal-title":"Cell"},{"key":"10.1016\/bs.acr.2025.06.005_bib100","doi-asserted-by":"crossref","unstructured":"Maury, S., Chevret, S., Thomas, X., Heim, D., Leguay, T., Huguet, F., & Dombret, H. Rituximab in B-Lineage Adult Acute Lymphoblastic Leukemia. New England Journal of Medicine, 375(11), 1044\u20131053. https:\/\/doi.org\/10.1056\/NEJMoa1605085.","DOI":"10.1056\/NEJMoa1605085"},{"issue":"4","key":"10.1016\/bs.acr.2025.06.005_bib101","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.molimm.2004.07.032","article-title":"2B4 (CD244) is a non-MHC binding receptor with multiple functions on natural killer cells and CD8+ T cells","volume":"42","author":"McNerney","year":"2005","journal-title":"Molecular Immunology"},{"issue":"Supplement 1","key":"10.1016\/bs.acr.2025.06.005_bib102","doi-asserted-by":"crossref","first-page":"3452","DOI":"10.1182\/blood-2022-163682","article-title":"CXCR4 (CD184) expression in pediatric AML is associated with bone marrow retention, specific disease characteristics, and worse outcomes: A report of 1004 patients from the children's oncology group AAML1031 protocol","volume":"140","author":"Menssen","year":"2022","journal-title":"Blood"},{"issue":"6","key":"10.1016\/bs.acr.2025.06.005_bib103","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1182\/blood.2021013156","article-title":"Effective therapy for AML with RUNX1 mutation by cotreatment with inhibitors of protein translation and BCL2","volume":"139","author":"Mill","year":"2022","journal-title":"Blood"},{"issue":"1","key":"10.1016\/bs.acr.2025.06.005_bib104","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1182\/blood.V93.1.96","article-title":"Single adult human CD34+\/Lin\u2212\/CD38\u2212 progenitors give rise to natural killer cells, B-lineage cells, dendritic cells, and myeloid cells","volume":"93","author":"Miller","year":"1999","journal-title":"Blood"},{"key":"10.1016\/bs.acr.2025.06.005_bib105","doi-asserted-by":"crossref","first-page":"104768","DOI":"10.1016\/j.exphem.2025.104768","article-title":"Ex vivo modelling reveals low levels of CKS1 inhibition boost haematopoiesis via AKT\/Foxo1 signalling","volume":"146","author":"Miranda","year":"2025","journal-title":"Experimental Hematology"},{"issue":"3","key":"10.1016\/bs.acr.2025.06.005_bib106","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1002\/(SICI)1096-8652(199911)62:3<159::AID-AJH5>3.0.CO;2-4","article-title":"Altered expression of CD45 isoforms in differentiation of acute myeloid leukemia","volume":"62","author":"Miyachi","year":"1999","journal-title":"American Journal of Hematology"},{"issue":"9","key":"10.1016\/bs.acr.2025.06.005_bib107","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/nri1917","article-title":"Balancing co-stimulation and inhibition with BTLA and HVEM","volume":"6","author":"Murphy","year":"2006","journal-title":"Nature Reviews. Immunology"},{"issue":"5","key":"10.1016\/bs.acr.2025.06.005_bib108","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1182\/blood-2013-01-480129","article-title":"Acute myeloid leukemia creates an arginase-dependent immunosuppressive microenvironment","volume":"122","author":"Mussai","year":"2013","journal-title":"Blood"},{"key":"10.1016\/bs.acr.2025.06.005_bib109","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.23049","article-title":"TAPBPR bridges UDP-glucose: Glycoprotein glucosyltransferase 1 onto MHC class I to provide quality control in the antigen presentation pathway","volume":"6","author":"Neerincx","year":"2017","journal-title":"Elife"},{"issue":"6","key":"10.1016\/bs.acr.2025.06.005_bib110","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1158\/2643-3230.BCD-23-0020","article-title":"Immune surveillance of acute myeloid leukemia is mediated by HLA-presented antigens on leukemia progenitor cells","volume":"4","author":"Nelde","year":"2023","journal-title":"Blood Cancer Discovery"},{"issue":"7633","key":"10.1016\/bs.acr.2025.06.005_bib111","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1038\/nature20598","article-title":"A 17-gene stemness score for rapid determination of risk in acute leukaemia","volume":"540","author":"Ng","year":"2016","journal-title":"Nature"},{"issue":"1","key":"10.1016\/bs.acr.2025.06.005_bib112","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1038\/s41467-019-08871-1","article-title":"Bone marrow central memory and memory stem T-cell exhaustion in AML patients relapsing after HSCT","volume":"10","author":"Noviello","year":"2019","journal-title":"Nature Communications"},{"issue":"12","key":"10.1016\/bs.acr.2025.06.005_bib113","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1038\/ni.2762","article-title":"A rheostat for immune responses: The unique properties of PD-1 and their advantages for clinical application","volume":"14","author":"Okazaki","year":"2013","journal-title":"Nature Immunology"},{"issue":"8","key":"10.1016\/bs.acr.2025.06.005_bib114","doi-asserted-by":"crossref","first-page":"4830","DOI":"10.4049\/jimmunol.0802902","article-title":"N-Glycosylation enhances presentation of a MHC class I-restricted epitope from tyrosinase 1","volume":"182","author":"Ostankovitch","year":"2009","journal-title":"The Journal of Immunology"},{"issue":"4","key":"10.1016\/bs.acr.2025.06.005_bib115","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1111\/imm.12665","article-title":"Functional exhaustion of CD4+ T cells induced by co-stimulatory signals from myeloid leukaemia cells","volume":"149","author":"Ozkazanc","year":"2016","journal-title":"Immunology"},{"issue":"1","key":"10.1016\/bs.acr.2025.06.005_bib116","doi-asserted-by":"crossref","first-page":"3153","DOI":"10.1038\/s41467-023-38113-4","article-title":"Leukemia relapse via genetic immune escape after allogeneic hematopoietic cell transplantation","volume":"14","author":"Pagliuca","year":"2023","journal-title":"Nature Communications"},{"issue":"3","key":"10.1016\/bs.acr.2025.06.005_bib117","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/leu.2008.339","article-title":"CTLA-4 genotype and relapse incidence in patients with acute myeloid leukemia in first complete remission after induction chemotherapy","volume":"23","author":"P\u00e9rez-Garc\u00eda","year":"2009","journal-title":"Leukemia: Official Journal of the Leukemia Society of America, Leukemia Research Fund, U. K"},{"issue":"12","key":"10.1016\/bs.acr.2025.06.005_bib118","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1038\/s41577-022-00707-2","article-title":"A guide to antigen processing and presentation","volume":"22","author":"Pishesha","year":"2022","journal-title":"Nature Reviews. Immunology"},{"issue":"13","key":"10.1016\/bs.acr.2025.06.005_bib119","doi-asserted-by":"crossref","first-page":"3515","DOI":"10.1158\/1078-0432.CCR-20-4271","article-title":"FDA approval summary: Gilteritinib for relapsed or refractory acute myeloid leukemia with a FLT3 mutation","volume":"27","author":"Pulte","year":"2021","journal-title":"Clinical Cancer Research: an Official Journal of the American Association for Cancer Research"},{"key":"10.1016\/bs.acr.2025.06.005_bib120","first-page":"4106","article-title":"A phase II study of post-remission therapy with pembrolizumab in older patients with acute myeloid leukemia","author":"Quann","year":"2024","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/bs.acr.2025.06.005_bib121","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s43042-021-00198-1","article-title":"The prospective prognostic value of the immune checkpoint BTLA expression in adult acute myeloid leukemia patients","volume":"22","author":"Radwan","year":"2021","journal-title":"Egyptian Journal of Medical Human Genetics"},{"issue":"Supplement 1","key":"10.1016\/bs.acr.2025.06.005_bib122","doi-asserted-by":"crossref","first-page":"2934","DOI":"10.1182\/blood-2023-174059","article-title":"Risk Stratification of patients with RUNX1-mutated acute myeloid leukemia","volume":"142","author":"Rausch","year":"2023","journal-title":"Blood"},{"issue":"9","key":"10.1016\/bs.acr.2025.06.005_bib123","doi-asserted-by":"crossref","first-page":"e480","DOI":"10.1016\/S2352-3026(19)30114-0","article-title":"Idarubicin, cytarabine, and nivolumab in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a single-arm, phase 2 study","volume":"6","author":"Ravandi","year":"2019","journal-title":"The Lancet Haematology"},{"issue":"Supplement 1","key":"10.1016\/bs.acr.2025.06.005_bib124","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1182\/blood-2018-99-109762","article-title":"A phase 1 first-in-human study of AMG 330, an Anti-CD33 bispecific T-cell engager (BiTE\u00ae) antibody construct, in relapsed\/refractory acute myeloid leukemia (R\/R AML)","volume":"132","author":"Ravandi","year":"2018","journal-title":"Blood"},{"issue":"15_suppl","key":"10.1016\/bs.acr.2025.06.005_bib125","doi-asserted-by":"crossref","first-page":"7508","DOI":"10.1200\/JCO.2020.38.15_suppl.7508","article-title":"Updated results from phase I dose-escalation study of AMG 330, a bispecific T-cell engager molecule, in patients with relapsed\/refractory acute myeloid leukemia (R\/R AML)","volume":"38","author":"Ravandi","year":"2020","journal-title":"Journal of Clinical Oncology"},{"issue":"3","key":"10.1016\/bs.acr.2025.06.005_bib126","doi-asserted-by":"crossref","DOI":"10.1038\/s41408-021-00453-z","article-title":"Nivolumab maintenance in high-risk acute myeloid leukemia patients: a single-arm, open-label, phase II study","volume":"11","author":"Reville","year":"2021","journal-title":"Blood Cancer Journal"},{"key":"10.1016\/bs.acr.2025.06.005_bib127","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.imlet.2018.01.009","article-title":"CD45 in human physiology and clinical medicine","volume":"196","author":"Rheinl\u00e4nder","year":"2018","journal-title":"Immunology Letters"},{"issue":"ement 1","key":"10.1016\/bs.acr.2025.06.005_bib128","doi-asserted-by":"crossref","first-page":"4204","DOI":"10.1182\/blood-2023-186378","article-title":"The impact of adding rituximab to the standard chemotherapy + TKI regimen in adults with philadelphia-positive B acute lymphoblastic leukemia: A multicenter retrospective study","volume":"142","author":"Rodriguez-Rodriguez","year":"2023","journal-title":"Blood"},{"issue":"13","key":"10.1016\/bs.acr.2025.06.005_bib129","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1182\/blood.2024025706","article-title":"Two-layered immune escape in AML is overcome by Fc\u03b3 receptor activation and inhibition of PGE2 signaling in NK cells","volume":"145","author":"Rothfu\u00df","year":"2025","journal-title":"Blood"},{"issue":"40","key":"10.1016\/bs.acr.2025.06.005_bib130","doi-asserted-by":"crossref","first-page":"64785","DOI":"10.18632\/oncotarget.11622","article-title":"CD45 phosphatase is crucial for human and murine acute myeloid leukemia maintenance through its localization in lipid rafts","volume":"7","author":"Saint-Paul","year":"2016","journal-title":"Oncotarget"},{"issue":"3","key":"10.1016\/bs.acr.2025.06.005_bib131","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1038\/modpathol.2016.202","article-title":"Overexpression and gene amplification of PD-L1 in cancer cells and PD-L1+ immune cells in Epstein\u2013Barr virus-associated gastric cancer: The prognostic implications","volume":"30","author":"Saito","year":"2017","journal-title":"Modern Pathology"},{"issue":"6","key":"10.1016\/bs.acr.2025.06.005_bib132","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1038\/s41375-024-02255-1","article-title":"AML\/T cell interactomics uncover correlates of patient outcomes and the key role of ICAM1 in T cell killing of AML","volume":"38","author":"Sayitoglu","year":"2024","journal-title":"Leukemia: Official Journal of the Leukemia Society of America, Leukemia Research Fund, U. K"},{"issue":"3","key":"10.1016\/bs.acr.2025.06.005_bib133","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1038\/s41416-021-01400-2","article-title":"Pan-cancer association of HLA gene expression with cancer prognosis and immunotherapy efficacy","volume":"125","author":"Schaafsma","year":"2021","journal-title":"British Journal of Cancer"},{"issue":"18","key":"10.1016\/bs.acr.2025.06.005_bib134","doi-asserted-by":"crossref","first-page":"5215","DOI":"10.1182\/bloodadvances.2023010477","article-title":"Phase 2 study of PD-1 blockade following autologous transplantation for patients with AML ineligible for allogeneic transplant","volume":"7","author":"Solomon","year":"2023","journal-title":"Blood Advances"},{"issue":"1","key":"10.1016\/bs.acr.2025.06.005_bib135","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41598-017-00290-w","article-title":"Evidence for C1q-mediated crosslinking of CD33\/LAIR-1 inhibitory immunoreceptors and biological control of CD33\/LAIR-1 expression","volume":"7","author":"Son","year":"2017","journal-title":"Scientific Reports"},{"issue":"669","key":"10.1016\/bs.acr.2025.06.005_bib136","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abj1270","article-title":"Targeting cancer glycosylation repolarizes tumor-associated macrophages allowing effective immune checkpoint blockade","volume":"14","author":"Stanczak","year":"2022","journal-title":"Science Translational Medicine"},{"issue":"Suppl 1","key":"10.1016\/bs.acr.2025.06.005_bib137","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1182\/blood-2019-127977","article-title":"Preliminary results from a phase 1 first-in-human study of AMG 673, a novel half-life extended (HLE) anti-CD33\/CD3 BiTE\u00ae (bispecific T-cell engager) in patients with relapsed\/refractory (R\/R) acute myeloid leukemia (AML)","volume":"134","author":"Subklewe","year":"2019","journal-title":"Blood"},{"issue":"11","key":"10.1016\/bs.acr.2025.06.005_bib138","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/S0167-5699(00)01698-4","article-title":"Immunoreceptor tyrosine-based inhibition motifs: Edited by\u00a0M. Da\u00ebron\u00a0and E. Vivier, Springer Verlag, 1999. \u00a376.50 (vii+179 pages) ISBN 3 540 65789 4","volume":"21","author":"Takei","year":"2000","journal-title":"Immunology Today"},{"issue":"1","key":"10.1016\/bs.acr.2025.06.005_bib139","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/2051-1426-1-13","article-title":"Immune evasion in acute myeloid leukemia: Current concepts and future directions","volume":"1","author":"Teague","year":"2013","journal-title":"Journal for ImmunoTherapy of Cancer"},{"issue":"1","key":"10.1016\/bs.acr.2025.06.005_bib140","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/2050-7771-2-4","article-title":"CD 123 is a membrane biomarker and a therapeutic target in hematologic malignancies","volume":"2","author":"Testa","year":"2014","journal-title":"Biomarker Research"},{"issue":"1","key":"10.1016\/bs.acr.2025.06.005_bib141","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/s41375-021-01350-x","article-title":"Catch me if you can: How AML and its niche escape immunotherapy","volume":"36","author":"Tettamanti","year":"2022","journal-title":"Leukemia: Official Journal of the Leukemia Society of America, Leukemia Research Fund, U. K"},{"issue":"7","key":"10.1016\/bs.acr.2025.06.005_bib142","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0131761","article-title":"The profile of T helper subsets in bone marrow microenvironment is distinct for different stages of acute myeloid leukemia patients and chemotherapy partly ameliorates these variations","volume":"10","author":"Tian","year":"2015","journal-title":"PLoS ONE"},{"issue":"4","key":"10.1016\/bs.acr.2025.06.005_bib143","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/s41591-019-0400-z","article-title":"Immune signature drives leukemia escape and relapse after hematopoietic cell transplantation","volume":"25","author":"Toffalori","year":"2019","journal-title":"Nature Medicine"},{"issue":"16","key":"10.1016\/bs.acr.2025.06.005_bib144","doi-asserted-by":"crossref","first-page":"4113","DOI":"10.3390\/cancers13164113","article-title":"A clinical phase 1B study of the CD3xCD123 bispecific antibody APVO436 in patients with relapsed\/refractory acute myeloid leukemia or myelodysplastic syndrome","volume":"13","author":"Uckun","year":"2021","journal-title":"Cancers"},{"issue":"7","key":"10.1016\/bs.acr.2025.06.005_bib145","doi-asserted-by":"crossref","first-page":"4510","DOI":"10.1128\/JVI.79.7.4510-4513.2005","article-title":"Complex memory T-cell phenotypes revealed by coexpression of CD62L and CCR7","volume":"79","author":"Unsoeld","year":"2005","journal-title":"Journal of Virology"},{"issue":"19","key":"10.1016\/bs.acr.2025.06.005_bib146","doi-asserted-by":"crossref","first-page":"5084","DOI":"10.1182\/blood-2011-07-365817","article-title":"Regulatory T cells in acute myelogenous leukemia: Is it time for immunomodulation?","volume":"118","author":"Ustun","year":"2011","journal-title":"Blood"},{"issue":"6","key":"10.1016\/bs.acr.2025.06.005_bib147","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1182\/blood.2020007732","article-title":"Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia","volume":"137","author":"Uy","year":"2021","journal-title":"Blood"},{"issue":"6","key":"10.1016\/bs.acr.2025.06.005_bib148","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.3324\/haematol.2019.229492","article-title":"Yttrium-90-labeled anti-CD45 antibody followed by a reduced-intensity hematopoietic cell transplantation for patients with relapsed\/refractory leukemia or myelodysplasia","volume":"105","author":"Vo","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/bs.acr.2025.06.005_bib149","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.canlet.2019.10.032","article-title":"Blocking migration of regulatory T cells to leukemic hematopoietic microenvironment delays disease progression in mouse leukemia model","volume":"469","author":"Wang","year":"2020","journal-title":"Cancer Letters"},{"key":"10.1016\/bs.acr.2025.06.005_bib150","doi-asserted-by":"crossref","first-page":"292","DOI":"10.3389\/fimmu.2017.00292","article-title":"Major histocompatibility complex (MHC) class I and MHC class II proteins: Conformational plasticity in antigen presentation","volume":"8","author":"Wieczorek","year":"2017","journal-title":"Frontiers in Immunology"},{"issue":"2","key":"10.1016\/bs.acr.2025.06.005_bib151","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1038\/s41375-021-01375-2","article-title":"Regulatory T cells promote the stemness of leukemia stem cells through IL10 cytokine-related signaling pathway","volume":"36","author":"Xu","year":"2022","journal-title":"Leukemia: Official Journal of the Leukemia Society of America, Leukemia Research Fund, U. K"},{"issue":"Supplement 1","key":"10.1016\/bs.acr.2025.06.005_bib152","first-page":"2727","article-title":"Regulatory T cells promote the stemness of acute myeloid leukemia cells through IL10 cytokine related signaling pathway","volume":"130","author":"Xu","year":"2017","journal-title":"Blood"},{"issue":"3","key":"10.1016\/bs.acr.2025.06.005_bib153","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1158\/2643-3230.BCD-23-0110","article-title":"Spatial mapping of hematopoietic clones in human bone marrow","volume":"5","author":"Young","year":"2024","journal-title":"Blood Cancer Discovery"},{"issue":"7","key":"10.1016\/bs.acr.2025.06.005_bib154","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1038\/s41419-020-2701-z","article-title":"PD-L1 promotes tumor growth and progression by activating WIP and \u03b2-catenin signaling pathways and predicts poor prognosis in lung cancer","volume":"11","author":"Yu","year":"2020","journal-title":"Cell Death & Disease"},{"issue":"3","key":"10.1016\/bs.acr.2025.06.005_bib155","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.hemonc.2015.11.006","article-title":"CD56 and RUNX1 isoforms in AML prognosis and their therapeutic potential","volume":"9","author":"Zaidi","year":"2016","journal-title":"Hematology\/Oncology and Stem Cell Therapy"},{"issue":"15_suppl","key":"10.1016\/bs.acr.2025.06.005_bib156","doi-asserted-by":"crossref","first-page":"7010","DOI":"10.1200\/JCO.2017.35.15_suppl.7010","article-title":"A phase I trial of ipilimumab (ipi) in patients (pts) with myelodysplastic syndromes (MDS) after hypomethylating agent (HMAs) failure","volume":"35","author":"Zeidan","year":"2017","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/bs.acr.2025.06.005_bib157","article-title":"AML-484 first results of a phase II study (STIMULUS-AML1) investigating Sabatolimab + Azacitidine + Venetoclax in patients with newly diagnosed acute myeloid leukemia (ND AML)","volume":"22","author":"Zeidan","year":"2022","journal-title":"Clinical Lymphoma, Myeloma and Leukemia"},{"issue":"6","key":"10.1016\/bs.acr.2025.06.005_bib158","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1158\/2643-3230.BCD-21-0070","article-title":"Phase II trial of Pembrolizumab after high-dose Cytarabine in relapsed\/refractory acute myeloid leukemia","volume":"2","author":"Zeidner","year":"2021","journal-title":"Blood Cancer Discovery"},{"issue":"9","key":"10.1016\/bs.acr.2025.06.005_bib159","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1182\/bloodadvances.2023011858","article-title":"Dual-targeting CD33\/CD123 NANOBODY T-cell engager with potent anti-AML activity and good safety profile","volume":"8","author":"Zeng","year":"2024","journal-title":"Blood Advances"},{"issue":"10","key":"10.1016\/bs.acr.2025.06.005_bib160","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1080\/10428194.2023.2230332","article-title":"Aberrant expression of CD5 in adult acute myeloid leukemia belonged to AML-MR, may represent a uniquely aggressive subcategory","volume":"64","author":"Zhang","year":"2023","journal-title":"Leukemia & Lymphoma"},{"issue":"1","key":"10.1016\/bs.acr.2025.06.005_bib161","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1080\/14653240500499507","article-title":"CTLA-4 blockade by a human MAb enhances the capacity of AML-derived DC to induce T-cell responses against AML cells in an autologous culture system","volume":"8","author":"Zhong","year":"2006","journal-title":"Cytotherapy"},{"issue":"17","key":"10.1016\/bs.acr.2025.06.005_bib162","doi-asserted-by":"crossref","first-page":"4501","DOI":"10.1182\/blood-2010-10-310425","article-title":"Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia","volume":"117","author":"Zhou","year":"2011","journal-title":"Blood"},{"key":"10.1016\/bs.acr.2025.06.005_bib163","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1489171","article-title":"Prediction of acute myeloid leukemia prognosis based on autophagy features and characterization of its immune microenvironment","volume":"15","author":"Zhu","year":"2024","journal-title":"Frontiers in Immunology"}],"container-title":["Advances in Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0065230X2500020X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0065230X2500020X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T10:51:05Z","timestamp":1763549465000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0065230X2500020X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"ISBN":["9780443344817"],"references-count":163,"URL":"https:\/\/doi.org\/10.1016\/bs.acr.2025.06.005","relation":{},"ISSN":["0065-230X"],"issn-type":[{"type":"print","value":"0065-230X"}],"subject":[],"published":{"date-parts":[[2025]]}}}